Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) in childhood is a rare disease with frequent progression to end-stage renal disease and a high recurrence after kidney transplantation. Eculizumab, a humanized monoclonal antibody that binds to complement protein C5, may be beneficial in the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorresteijn, Eiske M., van de Kar, Nicole C. A. J., Cransberg, Karlien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362716/
https://www.ncbi.nlm.nih.gov/pubmed/22399074
http://dx.doi.org/10.1007/s00467-012-2130-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362716/
https://www.ncbi.nlm.nih.gov/pubmed/22399074
http://dx.doi.org/10.1007/s00467-012-2130-z

Ejemplares similares